

A Simple, Modular Method for the Synthesis of 3,4,5-Trisubstituted Pyrazoles

Mark McLaughlin,* Karen Marcantonio, Cheng-yi Chen and Ian W. Davies

Department of Process Research, Merck Research Laboratories, Merck & Co., Inc.

Rahway, NJ 07065

mark_mclaughlin@merck.com

Supporting Information

Table of Contents:

General considerations	S2
General Procedures	S2-S4
Preparation of compound 6	S5-S6
Analytical data for compounds 7a-g	S7-S10
Analytical data for compounds 8a-g	S11-S13
Analytical data for compounds 9a-f	S14-S16
Analytical data for compounds 10 a-f	S17-S19
Analytical data for compounds 11-a-f	S20-S22
Analytical data for compounds 12, 13 and 14	S23-S24
NMR spectra for compound 6	S25
NMR spectra for compounds 7a-g	S26-S32
NMR spectra for compounds 8a-g	S33-S39
NMR spectra for compounds 9a-f	S40-S45
NMR spectra for compounds 10a-f	S46-S51
NMR spectra for compounds 11a-f	S52-S58
NMR spectra for compounds 12, 13 and 14	S59-S61
References	S62

General considerations: Screening reactions were conducted under a nitrogen atmosphere in 8 mL vials equipped with magnetic stir-bars and septa. Larger scale preparative reactions were conducted in standard RB-flasks under a nitrogen atmosphere. HPLC grade solvents were used with no additional purification/drying. K_3PO_4 was purchased as granular and ground to a powder before use. Stock solutions of HCl/MeOH were prepared by adding 10 mL AcCl to 100 mL MeOH over 5 min with ice-cooling. NMR spectra were recorded using a 400 MHz spectrometer; 1H NMR recorded at 400 MHz and ^{13}C recorded at 100 MHz. TLC was performed using 2.5 cm \times 7.5 cm glass-backed plates (silica gel 60, F₂₅₄, 250 μ m thickness). Flash column chromatography was performed using silica gel 60, 230-400 mesh.

General Procedure A

Suzuki Cross-Coupling of Pyrazole Boronic Esters and HCl salt formation: To an 8 mL vial equipped with stir-bar and septum was charged the pyrazole boronate (**6** or **10a-f**) (1 mmol), aryl halide (1 mmol) K_3PO_4 (300 mol%), $Pd(dbu)_2$ (2 mol%), $PCy_3.HBF_4$ (2.4 mol%) and 1,4-dioxane (3 mL). The heterogeneous mixture was agitated and purged with N_2 for 10 minutes before it was heated to 80 °C for 16 h. After this time, LC analysis of the gray mixture normally indicated > 98% conversion. The mixture was diluted with brine (30 mL) and MTBE (70 mL) and the separated organic was dried over Na_2SO_4 . The filtered MTBE solution was concentrated under reduced pressure and the crude residue was treated with HCl in MeOH (10 mL of stock solution) at rt. Isolation of the HCl salts (**8**) was achieved by dilution with MTBE and filtration of the resultant slurry. Alternatively, the THP-protected compounds (**7**) could be isolated following flash chromatography on silica gel using an appropriate mixture of EtOAc/hexanes as the eluent.

General Procedure B

THP Switch: To an 8 mL vial equipped with stir-bar and septum was charged the substrate **7** (1 mmol) followed by toluene (3 mL), DHP (100 mol%) and TFA (5 mol%).

The mixture was heated at 60 °C for 3 h then LC analysis indicated complete switching of the THP group. The mixture was diluted into saturated aqueous NaHCO₃ (30 mL) and MTBE (70 mL) then the separated organic phase was washed with brine (30 mL) and dried over Na₂SO₄. The filtered MTBE solution was concentrated under reduced pressure and the switched THP product **9** was isolated following flash chromatography on silica gel using an appropriate mixture of EtOAc/hexanes as the eluent.

General Procedure C

Conversion of Mono-Arylpyrazole HCl Salts into Switched THP Products: The HCl salt **8** (5 mmol) was partitioned between saturated aqueous Na₂CO₃ (30 mL) and EtOAc (70 mL). The separated organic phase was washed with brine (30 mL) then dried over Na₂SO₄ before it was filtered and concentrated under reduced pressure. The crude residue was treated with DHP (110 mol%) and TFA (5 mol%) in MeCN (15 mL) at 70 °C until LC analysis indicated complete conversion to the switched THP product **9**. [CAUTION! – These small scale experiments were conducted using the "all-in" procedure described. Slow addition of DHP would likely be preferable on larger scale as a means to control any potential exotherm, such as that observed during the preparation of compound **6** (*vide infra*).] The mixture was diluted into saturated aqueous NaHCO₃ (30 mL) and MTBE (70 mL) then the separated organic phase was washed with brine (30 mL) and dried over Na₂SO₄. The filtered MTBE solution was concentrated under reduced pressure and the switched THP product **9** was isolated following flash chromatography on silica gel using an appropriate mixture of EtOAc/hexanes as the eluent.

General Procedure D

Lithiation/(i-PrO)₃B Quench of THP-Pyrazoles Using n-BuLi: To a cooled (- 60 °C) THF solution of THP-pyrazole substrate (100 mol%, 10 mL/g, water content < 500 ppm) was charged *n*-BuLi (2.5 M in hexanes, 105 mol%), maintaining < - 40 °C. After 5 min, B(O*i*-Pr)₃ (110 mol%) was added and the mixture was allowed to warm to rt. After 1 h, pinacol (110 mol%) and AcOH (200 mol%) were added and the mixture was stirred at rt

for a further 1 h. The mixture was diluted into water and MTBE and the separated organic phase was washed with brine then dried over Na_2SO_4 . The filtered solution was solvent-switched into heptane and concentrated under reduced pressure to isolate the product by crystallization. Alternatively, in cases where the product **10** was an oil, the crude was purified by filtration over a pad of silica using an appropriate mixture of EtOAc/hexanes as the eluent.

General Procedure E

Lithiation/(i-PrO)₃B Quench of THP-Pyrazoles Using LDA: A 1 M THF solution of LDA was prepared by adding *n*-BuLi (2.5 M in hexanes, 120 mol%) to a THF solution of *i*-Pr₂NH (120 mol%) at -60 °C. The LDA solution was allowed to warm to 0-20 °C for 10 min before it was added to a cooled (-60 °C) THF solution of THP-pyrazole substrate (100 mol%, 10 mL/g, water content < 500 ppm) and B(O*i*-Pr)₃ (120 mol%) over 5 min. Upon complete addition of LDA, LC analysis indicated consumption of the starting pyrazole and the mixture was allowed to warm to room temperature. After 1 h, pinacol (110 mol%) and AcOH (200 mol%) were added and the mixture was stirred at rt for a further 1 h. The mixture was diluted into water and MTBE and the separated organic phase was washed with brine then dried over Na_2SO_4 . The filtered solution was solvent-switched into heptane and concentrated under reduced pressure to isolate the product by crystallization. Alternatively, in cases where the product **10** was an oil, the crude was purified by filtration over a pad of silica using an appropriate mixture of EtOAc/hexanes as the eluent.

Preparation of Pyrazole Boronate **6:**¹ To a 500 mL 3-neck R-B flask equipped with a dropping funnel, reflux condenser, temperature probe and nitrogen inlet was charged pyrazole (60.0 g, 0.88 mol, 100 mol%), toluene (100 mL) and TFA (3.40 mL, 44.1 mmol, 5 mol%). The slurry was heated to 80 °C then 3,4-dihydro-2*H*-pyran (DHP) (85 mL, 0.92


¹ Gerard, A.-L.; Bouillon, A.; Mahatsekake, C.; Collot, V.; Rault, S. *Tetrahedron Lett.*, **2006**, 47, 4665 - 4669.

mol, 105 mol%) was added over 1 h using the dropping funnel. [CAUTION! - As indicated in the manuscript, when this reaction is conducted following an "all-in" procedure, an exotherm is observed around 60 °C that can increase the batch temperature to > 100 °C. At this stage, the toluene/DHP reflux can mediate the batch temperature however this procedure is not recommended. The controlled addition of DHP at 80 °C ensures steady conversion and no accumulation of unreacted reagents.] The resultant pale yellow solution was aged for a further 1 h then LC analysis indicated complete conversion to the THP-pyrazole. The mixture was concentrated under reduced pressure to leave a crude pale yellow liquid (140 g) that was suitable for direct use in the subsequent boronate formation.


To a 3 L 4-neck R-B flask equipped with an overhead stirrer, reflux condenser, temperature probe and nitrogen inlet was charged the crude THP-pyrazole (assume 0.88 mol, 100 mol%) and THF (1 L, 100 ppm H₂O). The solution was cooled to - 50 °C and *n*-BuLi (2.5 M, 370 mL, 0.925 mol, 105 mol%) was added over 30 min using a dropping funnel (maintaining < - 40 °C). The resultant light brown solution was aged for 10 min at - 50 °C before B(O*i*-Pr)₃ (225 mL, 0.969 mol, 110 mol%) was added over 10 min using a dropping funnel (maintaining < - 30 °C). The solution was allowed to warm to room temperature then pinacol (115 g, 0.969 mol, 110 mol%) and AcOH (101 mL, 1.76 mol, 200 mol%) were added. (The addition of AcOH caused formation of a gel-like substance that is difficult to agitate unless an efficient overhead stirrer is used.) The mixture was aged at room temperature for 4 h before it was poured into saturated aqueous NH₄Cl (1 L) and heptane (1.2 L). The separated organic phase was washed with saturated aqueous NaHCO₃ (0.7 L) then brine (0.7 L) before it was dried over Na₂SO₄. The filtered solution was solvent-switched into heptane and concentrated under reduced pressure to isolate the product by crystallization at 5 °C. Filtration of the thick slurry afforded a cream solid, which was dried in a vacuum oven (with an N₂ bleed) at room temperature to give 196 g (80%): mp = 77-78 °C; ¹H NMR (400 MHz, CDCl₃) δ 1.31 (s, 12 H), 1.48-1.58 (m, 1H), 1.59-1.76 (m, 2H), 1.90-1.99 (m, 1H), 2.00-2.10 (m, 1H), 2.35-2.50 (m, 1H), 3.59-3.70 (m, 1H), 3.97-4.07 (m, 1H), 5.83 (dd, *J* = 10.0, 2.4 Hz, 1H), 6.72 (d, *J* = 1.6 Hz, 1H), 7.58 (d, *J* = 1.6 Hz, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 23.0, 24.6, 24.9, 25.1,

29.7, 67.9, 84.1, 86.3, 116.2, 139.2. HRMS calcd. for $C_8H_{14}BN_2O_3$ $[M+H (B(OH)_2)]^+$ 197.10975, found 197.11003.


Compounds 7a-g:




5-(4-Fluoro-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-pyrazole (7a): Following general procedure A, **7a** was obtained as a yellow solid (79%): mp = 58-59 °C; ¹H NMR (400 MHz, CDCl₃) δ 1.47-1.60 (m, 2H), 1.64-1.75 (m, 1H), 1.78-1.85 (m, 1H), 1.99-2.07 (m, 1H), 2.50-2.61 (m, 1H), 3.51-3.59 (m, 1H), 4.06-4.12 (m, 1H), 5.12 (d, *J* = 10.0, 2.4 Hz, 1H), 6.27 (d, *J* = 1.6 Hz, 1H), 7.08-7.14 (m, 2H), 7.45-7.50 (m, 2H), 7.56 (d, *J* = 1.6 Hz, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 22.9, 24.8, 29.6, 67.6, 84.1, 106.5, 115.6 (d, *J*_{CF} = 20.1 Hz), 126.5 (d, *J*_{CF} = 10.0 Hz), 130.8 (d, *J*_{CF} = 10.0 Hz), 139.3, 143.1, 163.0 (d, *J*_{CF} = 251.6 Hz). HRMS calcd. for C₉H₈FN₂ [(M-THP)+H]⁺ 163.06715, found 163.06792.




5-Phenyl-1-(tetrahydro-pyran-2-yl)-1H-pyrazole (7b): Following general procedure A, **7b** was obtained as a beige solid (76%): mp = 92-93 °C; ¹H NMR (400 MHz, CDCl₃) δ 1.50-1.62 (m, 2H), 1.70-1.80 (m, 1H), 1.81-1.89 (m, 1H), 2.02-2.10 (m, 1H), 2.54-2.65 (m, 1H), 3.56-3.63 (m, 1H), 4.10-4.17 (m, 1H), 5.22 (dd, *J* = 10.0, 2.4 Hz, 1H), 6.33 (d, *J* = 1.6 Hz, 1H), 7.40-7.49 (m, 3H), 7.51-7.55 (m, 2H), 7.61 (d, *J* = 1.6 Hz, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 23.1, 25.0, 29.9, 67.9, 84.3, 106.4, 128.7, 128.6, 129.2, 130.6, 139.6, 144.3. HRMS calcd. for C₉H₉N₂ [(M-THP)+H]⁺ 145.07657, found 145.07703.



3-[2-(Tetrahydro-pyran-2-yl)-2H-pyrazol-3-yl]-pyridine (7c): Following general procedure A, **7c** was obtained as a colorless oil (68%): ^1H NMR (400 MHz, CDCl_3) δ 1.52-1.65 (m, 2H), 1.68-1.82 (m, 1H), 1.85-1.93 (m, 1H), 2.04-2.14 (m, 1H), 2.53-2.65 (m, 1H), 3.55-3.65 (m, 1H), 4.09-4.17 (m, 1H), 5.16 (dd, J = 10.0, 2.4 Hz, 1H), 6.41 (d, J = 2.0 Hz, 1H), 7.41 (dd, J = 7.6, 4.8 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.87 (ddd, J = 7.6, 2.4, 1.6 Hz, 1H), 8.67 (dd, J = 4.8, 1.6 Hz, 1H), 8.78 (d, J = 2.4 Hz, 1H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 23.0, 24.9, 29.7, 67.8, 84.5, 107.5, 123.5, 126.8, 136.4, 139.7, 140.9, 149.8 (2 overlapping signals). HRMS calcd. for $\text{C}_8\text{H}_8\text{N}_3$ [(M-THP)+H] $^+$ 146.07182, found 146.07130.




1-(Tetrahydro-pyran-2-yl)-5-o-tolyl-1H-pyrazole (7d): Following general procedure A, **7d** was obtained as a yellow oil (77%): ^1H NMR (400 MHz, CDCl_3) δ 1.44-1.57 (m, 2H), 1.63-1.74 (m, 1H), 1.78-1.85 (m, 1H), 1.97-2.07 (m, 1H), 2.19 (s, 3H), 2.44-2.57 (m, 1H), 3.35-3.44 (m, 1H), 3.99-4.06 (m, 1H), 4.92 (dd, J = 10.0, 2.4 Hz, 1H), 6.23 (d, J = 1.6 Hz, 1H), 7.21-7.39 (m, 4H), 7.65 (d, J = 1.6 Hz, 1H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 20.1, 23.0, 25.0, 30.1, 68.0, 84.2, 107.1, 125.7, 129.1, 130.2, 130.3, 130.7, 138.0, 139.6, 142.7. HRMS calcd. for $\text{C}_{10}\text{H}_{11}\text{N}_2$ [(M-THP)+H] $^+$ 159.09222, found 159.09314.




4-[2-(Tetrahydro-pyran-2-yl)-2H-pyrazol-3-yl]-benzoic acid ethyl ester (7e):

Following general procedure A, **7e** was obtained as a yellow oil (77%): ^1H NMR (400 MHz, CDCl_3) δ 1.39 (t, J = 7.2 Hz, 3H), 1.47-1.59 (m, 2H), 1.69-1.77 (m, 1H), 1.79-1.86 (m, 1H), 2.01-2.08 (m, 1H), 2.50-2.61 (m, 1H), 3.54-3.61 (m, 1H), 4.08-4.14 (m, 1H), 4.39 (q, J = 7.2 Hz, 2H), 5.17 (dd, J = 10.0, 2.4 Hz, 1H), 6.37 (d, J = 2.0 Hz, 1H), 7.58 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 2.0 Hz, 1H), 8.11 (d, J = 8.8 Hz, 2H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 14.4, 23.1, 24.9, 29.8, 61.2, 37.8, 84.5, 107.2, 129.0, 129.9, 130.6, 134.8, 139.6, 143.3, 166.2. HRMS calcd. for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}_2$ [(M-THP)+H] $^+$ 217.09770, found 217.09848.




3-[2-(Tetrahydro-pyran-2-yl)-2H-pyrazol-3-yl]-benzonitrile (7f): Following general procedure A, **7f** was obtained as a yellow oil (80%): ^1H NMR (400 MHz, CDCl_3) δ 1.50-1.61 (m, 2H), 1.65-1.76 (m, 1H), 1.80-1.88 (m, 1H), 2.01-2.11 (m, 1H), 2.49-2.61 (m, 1H), 3.55-3.63 (m, 1H), 4.08-4.15 (m, 1H), 5.09 (dd, J = 10.0, 2.4 Hz, 1H), 6.37 (d, J = 1.6 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.58 (d, J = 1.6 Hz, 1H), 7.69 (d, J = 7.6 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.83 (s, 1H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 22.8, 24.8, 29.5, 67.6, 84.4, 107.4, 113.0, 118.3, 129.7, 131.8, 132.0, 132.4, 133.3, 139.6, 141.8. HRMS calcd. for $\text{C}_{10}\text{H}_8\text{N}_3$ [(M-THP)+H] $^+$ 170.07182, found 170.07215.




4-[2-(Tetrahydro-pyran-2-yl)-2H-pyrazol-3-yl]-benzonitrile (7g): Following general procedure A, **7g** was obtained as a yellow oil (81%): ^1H NMR (400 MHz, CDCl_3) δ 1.50-1.65 (m, 2H), 1.68-1.79 (m, 1H), 1.83-1.90 (m, 1H), 2.03-2.16 (m, 1H), 2.50-2.64 (m, 1H), 3.53-3.66 (m, 1H), 4.08-4.18 (m, 1H), 5.14 (dd, J = 10.0, 2.4 Hz, 1H), 6.40 (d, J = 1.6 Hz, 1H), 7.62 (d, J = 1.6 Hz, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 22.9, 24.9, 29.7, 67.8, 84.6, 107.7, 112.4, 118.5, 129.7, 132.6, 135.1, 139.7, 142.4. HRMS calcd. for $\text{C}_{10}\text{H}_8\text{N}_3$ $[(\text{M-THP})+\text{H}]^+$ 170.07182, found 170.07240.


Compounds 8a-g:



5-(4-Fluoro-phenyl)-1*H*-pyrazole hydrochloride (8a): Following general procedure A, **8a** was obtained as an off-white solid (84%): mp = 162-163 °C; ¹H NMR (400 MHz, DMSO) δ 6.98 (d, *J* = 2.4 Hz, 1H), 7.28 (dd, *J* = 8.4, 5.6 Hz, 2H), 7.98 (dd, *J* = 8.4, 5.6 Hz, 2H), 8.08 (d, *J* = 2.4 Hz, 1H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 103.5, 116.1 (d, *J*_{CF} = 20.1 Hz), 126.0, 128.6 (d, *J*_{CF} = 10.0 Hz), 133.8, 146.1, 163.6 (d, *J*_{CF} = 251.6 Hz). HRMS calcd. for C₉H₈FN₂ [M+H]⁺ 163.06715, found 163.06749.




5-Phenyl-1*H*-pyrazole hydrochloride (8b):² Following general procedure A, **8b** was obtained as an off-white solid (81%): mp = 152-154 °C; ¹H NMR (400 MHz, DMSO) δ 7.06 (d, *J* = 2.4 Hz, 1H), 7.29-7.41 (m, 3H), 7.93 (d, *J* = 7.2 Hz, 2H), 8.22 (d, *J* = 2.4 Hz); ¹³C {¹H} NMR (100 MHz, DMSO) δ 104.3, 126.8, 127.9, 129.3, 130.2, 134.6, 146.6. HRMS calcd. for C₉H₉N₂ [M+H]⁺ 145.07657, found 145.07693.




3-(2*H*-Pyrazol-3-yl)-pyridine hydrochloride (8c):³ Following general procedure A, **8c** was obtained as an off-white solid (70%): mp = 263-264 °C; ¹H NMR (400 MHz, DMSO) δ 7.09 (d, *J* = 2.4 Hz, 1H), 7.94 (d, *J* = 2.4 Hz, 1H), 8.08 (dd, *J* = 8.0, 5.6 Hz, 1H), 8.81 (d, *J* = 5.6 Hz, 1H), 8.94 (d, *J* = 8.0 Hz, 1H), 9.30 (s, 1H); ¹³C {¹H} NMR (100


MHz, DMSO) δ 103.8, 127.6, 131.6, 133.0, 137.5, 139.6, 141.2, 143.9. HRMS calcd. for $C_8H_8N_3$ $[M+H]^+$ 146.07182, found 146.07270.




5-o-Tolyl-1H-pyrazole hydrochloride (8d): Following general procedure A, **8d** was obtained as an off-white solid (81%): mp = 147-150 °C; 1H NMR (400 MHz, DMSO) δ 2.39 (s, 3H), 6.73 (d, J = 2.4 Hz, 1H), 7.25-7.34 (m, 3H), 7.51 (d, J = 7.2 Hz, 1H), 8.09 (d, J = 2.4 Hz, 1H); ^{13}C { 1H } NMR (100 MHz, DMSO) δ 20.6, 106.2, 126.1, 129.0, 129.2, 129.4, 130.9, 133.3, 136.0, 146.3. HRMS calcd. for $C_{10}H_{11}N_2$ $[M+H]^+$ 159.09222, found 159.09252.



4-(2H-Pyrazol-3-yl)-benzoic acid ethyl ester hydrochloride (8e): Following general procedure A, **8e** was obtained as an off-white solid (88%): mp = 194-195 °C; 1H NMR (400 MHz, DMSO) δ 1.33 (t, J = 7.2 Hz, 3H), 4.31 (q, J = 7.2 Hz, 2H), 6.85 (d, J = 2.4 Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.93-8.01 (m, 4H); ^{13}C { 1H } NMR (100 MHz, DMSO) δ 14.2, 60.7, 103.1, 125.4, 128.8, 129.7, 132.3, 136.8, 147.3, 165.5. HRMS calcd. for $C_{12}H_{13}N_2O_2$ $[M+H]^+$ 217.09770, found 217.09713.




3-(2*H*-Pyrazol-3-yl)-benzonitrile hydrochloride (8f**):** Following general procedure A, **8f** was obtained as a white solid (82%): mp = 168-169 °C; ¹H NMR (400 MHz, DMSO) δ 6.98 (br s, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.74 (d, *J* = 8.0 Hz, 1H), 7.95 (br s, 1H), 8.19 (d, *J* = 8.0 Hz, 1H), 8.29 (br s, 1H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 103.6, 112.2, 118.7, 129.2, 130.2 (2 overlapping signals), 131.8, 132.6, 132.8, 146.2. HRMS calcd. for C₁₀H₈N₃ [M+H]⁺ 170.07182, found 170.07101.




4-(2*H*-Pyrazol-3-yl)-benzonitrile hydrochloride(8g**):** Following general procedure A, **8g** was obtained as a white solid (85%): mp = 200-201 °C; ¹H NMR (400 MHz, DMSO) δ 6.96 (d, *J* = 2.4 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.94 (d, *J* = 2.4 Hz, 1H), 8.02 (d, *J* = 8.4 Hz, 2H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 104.0, 110.5, 118.9, 126.3, 132.8, 132.9, 135.8, 146.5. HRMS calcd. for C₁₀H₈N₃ [M+H]⁺ 170.07182, found 170.07122.


Compounds 9a-f:




3-(4-Fluoro-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-pyrazole (9a): Following general procedure B, **9a** was obtained as a colorless oil (86%): ^1H NMR (400 MHz, CDCl_3) δ 1.58-1.77 (m, 3H), 2.02-2.23 (m, 3H), 3.69-3.77 (m, 1H), 4.07-4.14 (m, 1H), 5.43 (dd, J = 10.0, 2.4 Hz, 1H), 6.56 (d, J = 2.4 Hz, 1H), 7.04-7.11 (m, 2H), 7.63 (d, J = 2.4 Hz, 1H), 7.77-7.82 (m, 2H); ^{13}C $\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 22.6, 25.1, 30.7, 68.0, 87.9, 103.3, 115.5 (d, J_{CF} = 20.1 Hz), 127.6, 129.1, 129.8, 150.9, 162.7 (d, J_{CF} = 241.5 Hz). HRMS calcd. for $\text{C}_9\text{H}_8\text{FN}_2$ [(M-THP)+H] $^+$ 163.06715, found 163.06724.




3-Phenyl-1-(tetrahydro-pyran-2-yl)-1H-pyrazole (9b): Following general procedure B, **9b** was obtained as a colorless oil (78%): ^1H NMR (400 MHz, CDCl_3) δ 1.56-1.74 (m, 3H), 2.00-2.23 (m, 3H), 3.67-3.76 (m, 1H), 4.06-4.14 (m, 1H), 5.43 (dd, J = 10.0, 2.4 Hz, 1H), 6.63 (d, J = 2.4 Hz, 1H), 7.34 (t, J = 7.2 Hz, 1H), 7.41 (t, J = 7.2 Hz, 2H), 7.64 (d, J = 2.4 Hz, 1H), 7.87 (d, J = 7.2 Hz, 2H); ^{13}C $\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 22.5, 25.0, 30.6, 67.9, 87.8, 103.4, 125.8, 127.7, 128.6, 128.9, 133.5, 151.5. HRMS calcd. for $\text{C}_9\text{H}_9\text{N}_2$ [(M-THP)+H] $^+$ 145.07657, found 145.07702.



3-[1-(Tetrahydro-pyran-2-yl)-1*H*-pyrazol-3-yl]-pyridine (9c): Following general procedure B, **9c** was obtained as a colorless oil (68%): ^1H NMR (400 MHz, CDCl_3) δ 1.45-1.63 (m, 3H), 1.89-2.12 (m, 3H), 3.57-3.64 (m, 1H), 3.94-4.01 (m, 1H), 5.32 (dd, J = 10.0, 2.4 Hz, 1H), 6.54 (d, J = 2.4 Hz, 1H), 7.20 (dd, J = 8.0, 4.8 Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 8.03 (dt, J = 8.0, 2.0 Hz, 1H), 8.44 (dd, J = 4.8, 1.6 Hz, 1H), 8.97 (d, J = 2.0 Hz, 1H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 22.3, 24.8, 30.4, 67.7, 87.5, 103.3, 123.3, 129.2, 138.8, 147.1, 148.4, 148.6. HRMS calcd. for $\text{C}_8\text{H}_8\text{N}_3$ [(M-THP)+H] $^+$ 146.07182, found 146.07095.




1-(Tetrahydro-pyran-2-yl)-3-*o*-tolyl-1*H*-pyrazole (9d): Following general procedure B, **9d** was obtained as a colorless oil (81%): ^1H NMR (400 MHz, CDCl_3) δ 1.57-1.77 (m, 3H), 2.02-2.24 (m, 3H), 2.49 (s, 3H), 3.69-3.78 (m, 1H), 4.06-4.14 (m, 1H), 5.46 (dd, J = 10.0, 2.4 Hz, 1H), 6.47 (d, J = 2.4 Hz, 1H), 7.20-7.26 (m, 3H), 7.56-7.61 (m, 1H), 7.66 (d, J = 2.4 Hz, 1H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 21.3, 22.6, 25.1, 30.7, 67.8, 87.8, 106.5, 125.8, 127.7, 127.9, 129.5, 130.8, 133.4, 136.2, 151.9. HRMS calcd. for $\text{C}_{10}\text{H}_{11}\text{N}_2$ [(M-THP)+H] $^+$ 159.09222, found 159.09259.




4-[1-(Tetrahydro-pyran-2-yl)-1*H*-pyrazol-3-yl]-benzoic acid ethyl ester (9e): Following general procedure B, **9e** was obtained as a colorless oil (85%): ^1H NMR (400 MHz, CDCl_3) δ 1.36 (t, J = 7.2 Hz, 3H), 1.51-1.70 (m, 3H), 1.95-2.18 (m, 3H), 3.63-3.70 (m, 1H), 4.01-4.07 (m, 1H), 4.35 (q, J = 7.2 Hz, 2H), 5.39 (dd, J = 9.6, 2.4 Hz, 1H), 6.63 (d, J = 2.4 Hz, 1H), 7.61 (d, J = 2.4 Hz, 1H), 7.88 (d, J = 8.4 Hz, 2H), 8.05 (d, J = 8.4 Hz,

2H); ^{13}C $\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 14.4, 22.5, 25.0, 30.7, 60.9, 67.9, 87.9, 104.0, 125.6, 129.3, 129.5, 130.0, 137.8, 150.5, 166.6. HRMS calcd. for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}_2$ [(M-THP)+H] $^+$ 217.09770, found 217.09813.




3-[1-(Tetrahydro-pyran-2-yl)-1H-pyrazol-3-yl]-benzonitrile (9f): Following general procedure B, **9f** was obtained as a white solid (83%): mp = 87-88 °C; ^1H NMR (400 MHz, CDCl_3) δ 1.55-1.75 (m, 3H), 1.98-2.21 (m, 3H), 3.66-3.74 (m, 1H), 4.03-4.10 (m, 1H), 5.39 (dd, J = 10.0, 2.4 Hz, 1H), 6.60 (d, J = 2.0 Hz, 1H), 7.44 (t, J = 8.0 Hz, 1H), 7.53 (dt, J = 8.0, 1.6 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 8.01 (d, J = 8.0 Hz, 1H), 8.11 (t, J = 1.6 Hz, 1H); ^{13}C $\{\text{H}\}$ NMR (100 MHz, CDCl_3) δ 22.4, 24.9, 30.5, 67.9, 87.8, 103.5, 112.6, 118.9, 129.2, 129.3, 129.5, 129.9, 130.9, 134.7, 149.3. HRMS calcd. for $\text{C}_{10}\text{H}_8\text{N}_3$ [(M-THP)+H] $^+$ 170.07182, found 170.07248.

Compounds 10a-f:




3-(4-Fluoro-phenyl)-1-(tetrahydro-pyran-2-yl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (10a):

Following general procedure D, **10a** was obtained as a white solid (79%): mp = 104-105 °C; ¹H NMR (400 MHz, CDCl₃) δ 1.37 (s, 12H), 1.55-1.62 (m, 1H), 1.69-1.81 (m, 2H), 1.97-2.05 (m, 1H), 2.09-2.17 (m, 1H), 2.51-2.63 (m, 1H), 3.65-3.74 (m, 1H), 4.05-4.12 (m, 1H), 5.87 (dd, *J* = 10.0, 2.4 Hz, 1H), 7.00 (s, 1H), 7.02-7.09 (m, 2H), 7.77-7.85 (m, 2H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 23.0, 24.8, 25.0, 25.2, 29.8, 68.0, 84.3, 86.6, 113.3, 115.4 (d, *J*_{CF} = 20.1 Hz), 127.6 (d, *J*_{CF} = 10.0 Hz), 129.8, 150.6, 162.5 (d, *J*_{CF} = 251.6 Hz). HRMS calcd. for C₁₄H₁₇BFN₂O₃ [M+H (B(OH)₂)]⁺ 291.13163, found 291.13291.




3-Phenyl-1-(tetrahydro-pyran-2-yl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (10b):


Following general procedure D, **10b** was obtained as a white solid (72%): mp = 99-100 °C ¹H NMR (400 MHz, CDCl₃) δ 1.38 (s, 12H), 1.56-1.63 (m, 1H), 1.70-1.82 (m, 2H), 1.99-2.07 (m, 1H), 2.11-2.19 (m, 1H), 2.55-2.66 (m, 1H), 3.65-3.75 (m, 1H), 4.04-4.14 (m, 1H), 5.89 (dd, *J* = 10.0, 2.4 Hz, 1H), 7.08 (s, 1H), 7.25-7.32 (t, *J* = 7.2 Hz, 1H), 7.38-7.42 (t, *J* = 7.2 Hz, 2H), 7.83-7.89 (d, *J* = 7.2 Hz, 2H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 23.0, 24.8, 25.1, 25.2, 29.8, 67.9, 84.3, 86.6, 113.6, 126.1, 127.6, 128.5, 133.6, 151.5. HRMS calcd. for C₁₄H₁₈BN₂O₃ [M+H (B(OH)₂)]⁺ 273.14105, found 273.14242.




3-[1-(Tetrahydro-pyran-2-yl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazol-3-yl]-pyridine (10c): Following general procedure D, **10c** was obtained as a colorless oil (67%): ^1H NMR (400 MHz, CDCl_3) δ 1.36 (s, 12H), 1.55-1.62 (m, 1H), 1.69-1.79 (m, 2H), 1.97-2.04 (m, 1H), 2.08-2.17 (m, 1H), 2.50-2.62 (m, 1H), 3.65-3.73 (m, 1H), 4.05-4.11 (m, 1H), 5.88 (dd, J = 10.0, 2.4 Hz, 1H), 7.09 (s, 1H), 7.29 (dd, J = 8.0, 4.0 Hz, 1H), 8.14 (ddd, J = 8.0, 4.0, 2.0 Hz, 1H), 8.51 (d, J = 4.0 Hz, 1H), 9.04 (s, 1H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 22.9, 24.8, 25.0, 25.1, 29.7, 68.0, 84.4, 86.7, 113.6, 123.5, 129.4, 133.2, 147.5, 148.5, 148.6. HRMS calcd. for $\text{C}_{13}\text{H}_{17}\text{BN}_3\text{O}_3$ [$\text{M}+\text{H}$ ($\text{B}(\text{OH})_2$)] $^+$ 274.13630, found 274.1371.



1-(Tetrahydro-pyran-2-yl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3-o-tolyl-1H-pyrazole (10d): Following general procedure D, **10d** was obtained as a white solid (72%): mp = 109-110 °C; ^1H NMR (400 MHz, CDCl_3) δ 1.38 (s, 12H), 1.55-1.62 (m, 1H), 1.69-1.79 (m, 2H), 2.01-2.09 (m, 1H), 2.10-2.18 (m, 1H), 2.51 (s, 3H), 2.53-2.59 (m, 1H), 3.67-3.75 (m, 1H), 4.05-4.11 (m, 1H), 5.90 (dd, J = 10.0, 2.4 Hz, 1H), 6.92 (s, 1H), 7.18-7.25 (m, 3H), 7.56-7.61 (m, 1H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 21.4, 22.9, 24.8, 25.1, 25.2, 29.7, 67.7, 84.2, 86.4, 116.5, 125.7, 127.5, 129.6, 130.7, 133.3, 136.3, 151.6. HRMS calcd. for $\text{C}_{15}\text{H}_{20}\text{BN}_2\text{O}_3$ [$\text{M}+\text{H}$ ($\text{B}(\text{OH})_2$)] $^+$ 287.15670, found 287.15720.




4-[1-(Tetrahydro-pyran-2-yl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazol-3-yl]-benzoic acid ethyl ester (10e): Following general procedure E, **10e** was obtained as a white solid (82%): ^1H NMR (400 MHz, CDCl_3) δ 1.36 (s, 12H), 1.39 (t, J = 7.2 Hz, 3H), 1.55-1.62 (m, 1H), 1.68-1.81 (m, 2H), 1.91-2.06 (m, 1H), 2.08-2.16 (m, 1H), 2.51-2.63 (m, 1H), 3.64-3.74 (m, 1H), 4.04-4.13 (m, 1H), 4.37 (q, J = 7.2 Hz, 2H), 5.88 (dd, J = 10.0, 2.4 Hz, 1H), 7.12 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 8.05 (d, J = 8.4 Hz, 2H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 14.5, 22.9, 24.8, 25.0, 25.1, 29.7, 60.9, 68.0, 84.4, 86.7, 114.1, 125.7, 129.3, 129.9, 137.8, 150.3, 166.7. HRMS calcd. for $\text{C}_{17}\text{H}_{22}\text{BN}_2\text{O}_5$ $[\text{M}+\text{H} (\text{B}(\text{OH})_2)]^+$ 345.16218, found 345.16294.




3-[1-(Tetrahydro-pyran-2-yl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazol-3-yl]-benzonitrile (10f): Following general procedure E, **10f** was obtained as a colorless oil (81%): ^1H NMR (400 MHz, CDCl_3) δ 1.36 (s, 12H), 1.54-1.63 (m, 1H), 1.66-1.82 (m, 2H), 1.96-2.04 (m, 1H), 2.07-2.17 (m, 1H), 2.48-2.60 (m, 1H), 3.65-3.74 (m, 1H), 4.03-4.12 (m, 1H), 5.88 (dd, J = 10.0, 2.4 Hz, 1H), 7.06 (s, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 8.03 (dd, J = 8.0, 1.6 Hz, 1H), 8.16 (s, 1H); ^{13}C { ^1H } NMR (100 MHz, CDCl_3) δ 22.9, 24.8, 25.0, 29.7, 68.0, 84.5, 86.7, 112.7, 113.6, 119.0, 129.4, 129.5, 130.1, 130.8, 134.8, 149.2. HRMS calcd. for $\text{C}_{15}\text{H}_{17}\text{BN}_3\text{O}_3$ $[\text{M}+\text{H} (\text{B}(\text{OH})_2)]^+$ 298.13630, found 298.13710.


Compounds 11a-f:




5-(4-Fluoro-phenyl)-3-phenyl-1*H*-pyrazole hydrochloride (11a):⁴ Following general procedure A, **11a** was obtained as a white solid (83%): mp = 227-228 °C; ¹H NMR (400 MHz, DMSO) δ 7.26-7.35 (m, 3H), 7.37 (d, *J* = 7.2 Hz, 1H), 7.46 (t, *J* = 7.2 Hz, 2H), 7.91 (d, *J* = 7.2 Hz, 2H), 7.94-7.99 (m, 2H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 100.4, 115.8, 115.9 (d, *J*_{CF} = 20.1 Hz), 125.7, 126.9, 127.9 (d, *J*_{CF} = 10.0 Hz), 128.7, 129.0, 129.8, 146.8 (d, *J*_{CF} = 20.1 Hz), 162.2 (d, *J*_{CF} = 251.5 Hz). HRMS calcd. for C₁₅H₁₂FN₂ [M+H]⁺ 239.09845, found 239.09877.




4-(5-Phenyl-2*H*-pyrazol-3-yl)-benzonitrile hydrochloride (11b): Following general procedure A, **11b** was obtained as a white solid (88%): mp = 259-260 °C; ¹H NMR (400 MHz, DMSO) δ 7.27-7.37 (m, 2H), 7.39-7.48 (m, 2H), 7.78-7.91 (m, 4H), 8.00-8.10 (m, 2H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 101.2, 110.3, 119.1, 125.6, 126.0, 128.5, 129.1, 130.0, 133.0, 136.2, 146.5, 147.1. HRMS calcd. for C₁₆H₁₂N₃ [M+H]⁺ 246.10312, found 246.10405.



3-(5-Phenyl-2*H*-pyrazol-3-yl)-pyridine hydrochloride (11c): Following general procedure A, **11c** was obtained as an off-white solid (78%): mp = 242-243 °C; ¹H NMR (400 MHz, DMSO) δ 7.34 (t, *J* = 7.2 Hz, 1H), 7.44 (t, *J* = 7.2 Hz, 2H), 7.56 (s, 1H), 7.85 (d, *J* = 7.2 Hz, 2H), 8.10 (dd, *J* = 8.4, 5.6 Hz, 1H), 8.85 (d, *J* = 5.6 Hz, 1H), 8.97 (d, *J* = 8.4 Hz, 1H), 9.30 (s, 1H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 101.7, 125.5, 127.9, 128.6, 129.2, 129.3, 132.6, 137.5, 139.8, 141.3, 144.5, 145.6. HRMS calcd. for C₁₄H₁₂N₃ [M+H]⁺ 222.10312, found 222.10415.




3-Phenyl-5-o-tolyl-1*H*-pyrazole hydrochloride (11d): Following general procedure A, **11d** was obtained as a white solid (88%): 181-182 °C; ¹H NMR (400 MHz, DMSO) δ 2.45 (s, 3H), 7.10 (s, 1H), 7.26-7.34 (m, 3H), 7.37 (t, *J* = 7.6 Hz, 1H), 7.47 (t, *J* = 7.6 Hz, 2H), 7.55 (d, *J* = 7.6 Hz, 1H), 7.95 (d, *J* = 7.6 Hz, 2H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 20.9, 103.5, 125.9, 126.0, 128.8, 128.9, 129.1, 129.3, 129.8, 130.3, 131.1, 136.0, 146.8, 147.0. HRMS calcd. for C₁₆H₁₅N₂ [M+H]⁺ 235.12352, found 235.12299.




4-[5-(3-Cyano-phenyl)-1*H*-pyrazol-3-yl]-benzoic acid ethyl ester hydrochloride (11e):

Following general procedure A, **11e** was obtained as an off-white solid (79%): mp = 234-235 °C; ¹H NMR (400 MHz, DMSO) δ 1.35 (t, *J* = 7.2 Hz, 3H), 4.34 (q, *J* = 7.2 Hz, 2H), 7.50 (s, 1H), 7.68 (t, *J* = 8.4 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 1H), 7.97 (d, *J* = 8.4 Hz, 2H), 8.05 (d, *J* = 8.4 Hz, 2H), 8.17 (d, *J* = 8.4 Hz, 1H), 8.30 (s, 1H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 14.1, 60.7, 101.5, 112.0, 118.6, 125.1, 128.5, 129.0, 129.5, 129.8, 130.1, 131.2, 132.6, 135.2, 146.2 (2 overlapping signals), 165.4. HRMS calcd. for C₁₉H₁₆N₃O₂ [M+H]⁺ 318.12425, found 318.12478.



3-(5-Phenyl-2*H*-pyrazol-3-yl)-benzonitrile hydrochloride (11f): Following general procedure A, **11f** was obtained as a white solid (81%): mp = 221-222 °C; ¹H NMR (400 MHz, DMSO) δ 7.27-7.48 (m, 4H), 7.62 (t, *J* = 8.0 Hz, 1H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.85 (d, *J* = 8.0 Hz, 2H), 8.20 (d, *J* = 8.0 Hz, 1H), 8.31 (s, 1H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 100.9, 112.1, 118.8, 125.6, 128.6, 128.9, 129.1, 129.9, 130.0, 130.2, 131.6, 132.8, 146.5, 146.7. HRMS calcd. for C₁₆H₁₂N₃ [M+H]⁺ 246.10312, found 246.10421.

Compounds 12, 13 and 14:




3-[5-phenyl-2-(tetrahydro-pyran-2-yl)-2H-pyrazol-3-yl]-benzonitrile (12): Following general procedure A, **12** was obtained as a white solid (81%): mp = 135-136 °C; ¹H NMR (400 MHz, CDCl₃) δ 1.53-1.68 (m, 2H), 1.71-1.86 (m, 1H), 1.87-1.97 (m, 1H), 2.08-2.22 (m, 1H), 2.61-2.76 (m, 1H), 3.56-3.69 (m, 1H), 4.14-4.24 (m, 1H), 5.16 (dd, *J* = 10.0, 2.4 Hz, 1H), 6.71 (s, 1H), 7.33 (t, *J* = 7.2 Hz, 1H), 7.42 (t, *J* = 7.6 Hz, 2H), 7.61 (t, *J* = 7.6 Hz, 1H), 7.73 (d, *J* = 7.6 Hz, 1H), 7.85 (t, *J* = 7.6 Hz, 1H), 7.89 (d, *J* = 7.2 Hz, 2H), 7.93 (s, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 22.9, 24.9, 29.6, 67.7, 84.8, 104.7, 113.2, 118.5, 126.0, 128.1, 128.7, 129.8, 131.9, 132.2, 132.5, 133.0, 133.3, 143.3, 151.4. HRMS calcd. for C₁₆H₁₂N₃ [M+H]⁺ 246.10312, found 246.10329.



3-[4-Bromo-5-phenyl-2-(tetrahydro-pyran-2-yl)-2H-pyrazol-3-yl]-benzonitrile (13): A solution of **12** (0.50 g, 1.52 mmol, 100 mol%) in EtOAc (5 mL) was treated with NBS (0.40 g, 2.28 mmol, 150 mol%) and heated to 50 °C. After 2 h, LC analysis indicated complete conversion to **13** and the mixture was diluted with aqueous NaOH (0.5 M, 30 mL) and EtOAc (70 mL). The separated organic was washed with brine then dried over Na₂SO₄ before it was filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography on silica gel using an appropriate gradient of EtOAc/hexanes as the eluent. Compound **13** was isolated as a white solid (0.54 g, 87%): mp = 169-170 °C; ¹H NMR (400 MHz, CDCl₃) δ 1.52-1.61 (m, 2H), 1.67-1.78 (m, 1H), 1.85-1.93 (m, 1H), 2.07-2.16 (m, 1H), 2.53-2.65 (m, 1H), 3.50-3.58 (m, 1H), 4.09-4.16 (m, 1H), 5.08 (dd, *J* = 10.0, 2.4 Hz, 1H), 7.37-7.48 (m, 3H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.79 (d, *J* = 8.0 Hz, 1H), 7.86 (d, *J* = 8.0 Hz, 1H), 7.92-7.98 (m, 3H); ¹³C {¹H} NMR


(100 MHz, CDCl₃) δ 22.7, 24.8, 29.1, 67.7, 85.5, 94.3, 113.2, 118.3, 128.2, 128.4, 128.6, 129.7, 130.1, 132.0, 132.9, 133.9, 134.7, 141.0, 149.1. HRMS calcd. for C₁₆H₁₁BrN₃ [(M-THP)+H]⁺ 324.01363, found 324.01372.


3-[4-(4-Methoxy-phenyl)-5-phenyl-2*H*-pyrazol-3-yl]-benzonitrile hydrochloride (14):



Following general procedure A, compound **14** was obtained as a white solid (72%): mp = 219-220 °C; ¹H NMR (400 MHz, DMSO) δ 3.77 (s, 3H), 6.94 (d, *J* = 8.4 Hz, 2H), 7.10 (d, *J* = 8.4 Hz, 2H), 7.26-7.38 (m, 5H), 7.50 (t, *J* = 8.0 Hz, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.69-7.75 (m, 2H); ¹³C {¹H} NMR (100 MHz, DMSO) δ 55.1, 111.5, 114.4, 117.0, 118.6, 125.0, 127.4, 128.0, 128.5, 129.7, 130.5, 131.0, 131.7, 131.8, 133.7, 143.4, 144.4, 158.6. HRMS calcd. for C₂₃H₁₈N₃O [M+H]⁺ 352.14499, found 352.14574.











































8c

































































11a








11a

















11e






11e















References

1. Gérard, A.-L.; Bouillon, A.; Mahatsekake, C.; Collot, V.; Rault, S. *Tetrahedron Lett.* **2006**, 47, 4665–4669.
2. Polevoi, L. G.; Kudrin, A. N.; Grandberg, I. I.; Kost, A. N. *Izvestiya Timiryazevskoi Sel'skokhozyaistvennoi Akademii* **1968**, 1, 192-207.
3. Schunack, W. *Archiv der Pharmazie (Weinheim, Germany)* **1973**, 306, 934-942.
4. Joshi, K. C.; Pathak, V. N. *Indian Journal of Chemistry* **1973**, 11, 398-399.